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Background/aim: Raynaud’s phenomenon (RP) is not a rare health problem; global prevalence is about 3%–20%. Etiology and
pathophysiology of this pathology has not been clarified. There are many precipitating factors resulting in RP. Hyperhomocysteinemia
resulting from methylenetetrahydrofolate reductase (MTHFR) gene mutation may have a role in its etiology. The aim of this study was to
observe the frequency of RP in patients with MTFHR gene mutation and hyperhomocysteinemia. Possible relationships among vitamin
B12, folic acid, complete blood count (leukocytes and platelets), and c-reactive protein levels and RP were also analyzed.
Materials and methods: A total of 388 patients admitted to the internal medicine, hematology, and obstetric clinics of a university
hospital between January 2012 and April 2013 ranging in age from 21 to 83 (mean age 38.16 ± 13.1) were enrolled in the study. Eightyfive (21.9%) of the patients were male and 303 (78.1%) were female. MTHFR gene mutation was analyzed in 388 patients; 52 (13.4%)
were homozygous, 275 (70.9%) were heterozygous, and 61 (15.7%) were found to be negative for the MTHFR gene mutation and
accepted as a control group. Vitamin B12, folic acid, complete blood count (leukocytes and platelets), and c-reactive protein levels were
also analyzed.
Results: Homocysteine levels were higher in both heterozygous and homozygous groups (P < 0.05). RP was more frequently observed
in patients with elevated homocysteine levels (P < 0.05; X2 = 14.51). There was no significant relationship in other parameters studied.
Conclusion: RP was more frequently observed in the groups with the MTHFR mutation and hyperhomocysteinemia. Serum
homocysteine levels in patients with RP may be helpful for diagnosis.
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1. Introduction
Raynaud’s phenomenon (RP) is paroxysmal reversible
ischemia resulting from abnormal arterial vasospastic
response due to recurrent cold or emotional stress in the
extremities or peripheral parts of body [1]. Vasospasm
causes diminished arterial blood supply and paleness will
be observed, deoxygenation of hemoglobin will result in a
dark-blue color change reflecting cyanosis; finally, acidosis
will trigger vasodilatation and hyperemia and the color will
change to red [2]. When there’s no underlying condition,
RP is called primary Raynaud’s phenomenon (PRP). RP
may also be seen in some systemic diseases and conditions
(e.g., scleroderma, systemic lupus erythematosus, mixed
connective tissue disease, Sjögren’s syndrome, end-stage
renal disease, hand–arm vibration syndrome, antimigraine
drugs, beta blockers, cyclosporin, hypothyroidism,
pheochromocytoma, paraneoplastic syndrome, Buerger’s

disease), which is called secondary Raynaud’s phenomenon
(SRP) [3]. Various systemic factors are involved in the
pathogenesis of RP; increased alfa 2 adrenergic receptor
activity, especially under cold exposure, or endothelin-1
activity may result in vasoconstriction [4]; decreased
nitric oxide (NO) [5] or calcitonin gene related peptide
(CGRP) [6] may cause ineffective vasodilation; injury
to endothelium because of increased oxidative stress
may result in improper endothelial responses; platelet
activation, decreased fibrinolytic activity [7], decreased red
blood cell flexibility through arterioles [8], and increased
intravascular viscosity [9] may also have unfavorable
effects on blood flow. The prevalence of RP is reported
to be 3%–20% worldwide, and it is more frequently seen
in colder climates and in females [10,11]. Prevalence in
Turkey was reported to be 5.9% in one study [12] and 3.6%
in another [13].
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The 5,10-methylene tetrahydrofolate is the major
protein acting as a carbon donor in the remethylation
of homocysteine to methionine reaction. It is converted
to 5-methyl tetrahydrofolate by the methylene
tetrahydrofolate reductase (MTHFR) enzyme. Metabolism
of homocysteine requires vitamin B6, B12, and folate as
cofactors [14,15]. Several mutations and polymorphisms
in MTHFR enzyme genes will result in defective or
diminished enzyme function [16,17]. MTHFR enzyme
deficiency will cause higher homocysteine levels. A
slight decrease in MTHFR enzyme activity may result in
serious outcomes, particularly in arterial diseases such as
peripheral neuropathy, due to microangiopathy, stroke,
thrombosis, and coronary artery disease [18,19].
Hyperhomocysteinemia is found to be associated with
vascular pathologies by causing endothelial dysfunction
[20]. Hyperhomocysteinemia may be related to vitamin
B6, B12, and folate deficiencies; supplementation of folic
acid may improve homocysteine levels [21].
There is only one study reported in the literature
that examined homocysteine concentrations in patients
with MTHFR gene mutations and primary or systemic
sclerosis-associated RP [22].
The aim of this study was to compare patients
experiencing RP with normal MTHFR enzyme activity to
patients with mutations, and to evaluate the relationship
between MTHFR enzyme mutation, homocysteine levels,
and frequency of RP. Other purposes were to inspect
any possible relationships among vitamin B12, folic
acid, leukocytes and platelets (by complete blood count),
c-reactive protein levels, and RP.
2. Materials and methods
This study was approved by the local ethics committee
(38918275/0052). Informed written consent was obtained
from all of the patients participated in the study.

This is a prospective observational cohort study
conducted between January 2012 and April 2013 on patients
who were admitted to internal medicine, hematology, and
the gynecology and obstetrics clinics of a university hospital
for spontaneous abortus, recurrent abortus, varicose
veins, or deep venous thrombosis, and whose MTHFR
gene mutations were analyzed simultaneously with other
biochemical parameters [antinuclear antibody, vitamin
B12, folic acid, leukocytes and platelets (by complete blood
count), c-reactive protein levels after 12 h of fasting].
Homocysteine levels above 12 mmol/L were considered
high. The 677CT and 1298AC mutations were inspected by
real-time polymerase chain reaction (PCR) testing. DNA
isolation from peripheral blood was performed with a
QIAGEN QIAamp DNA blood kit (QIAGEN N.V., Venlo,
the Netherlands).
All of the patients included in the study were questioned
for the presence of RP. Existing RP was diagnosed after
an icy water stress test. Before testing, patients’ finger
temperatures were recorded and confirmed to be above
30 °C. Patients were requested to hold both hands in a
container filled with water and ice cubes for 30 s; finger
temperatures were recorded at 5 min intervals. Patients
whose finger temperatures were still below 30 °C after 10
min were accepted as having RP. Exclusion criteria are
shown in Table 1.
Patients with normal MTHFR enzyme activity
were accepted as the control group and heterozygous–
homozygous mutation-positive individuals constituted the
study groups.
Three hundred and eighty-eight patients were included
in the study. The ages of patients ranged from 21 to 83 years,
with a mean age of 38.16 ± 13.1 years. Eighty-five (21.9%)
of the patients were male and 303 (78.1%) were female.
MTHFR enzyme gene mutation was analyzed in all
patients; 61 (15.7%) were found to be negative for the

Table 1. Exclusion criteria of the patients.
1. Alcohol consumption, smoking, any kind of drug abuse
2. Anticoagulant medication usage for any reason
3. Patients with systemic or hematological disorders that may lead to thrombophilia (diabetes, chronic kidney disease, systemic lupus
erythematosus, rheumatoid arthritis)
4. The diagnosis of malignancy or being treated because of a malignancy
5. Hypothyroidism
6. Age; people younger than 20 years or older than 85 years
7. Did not want to participate in the study
8. Vitamin supplementation usage
9. Antinuclear antibody positivity
10. Elevated erythrocyte sedimentation rate and c-reactive protein levels
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MTHFR mutation and were accepted as the control group.
Two hundred and seventy-five patients (70.9%) had the
heterozygous mutation and 52 patients (13.4%) were
found to have the homozygous mutation.
2.1. Statistical analysis
SPSS for Windows 20.0 statistical software package
(IBM Corp., Armonk, NY, USA) was used for statistical
analysis of the data. The results of all the parameters of
the cases was given as the mean +/- standard deviation.
In the comparison, the one-way ANOVA, Student’s t-test,
and chi-squared tests were used. P < 0.05 was considered
statistically significant.
3. Results
Homocysteine levels in both heterozygous and
homozygous groups were higher than those of the control
group (P < 0.05). RP was observed more frequently in
patients with elevated homocysteine levels (P < 0.05, X2
= 14.51). There was no significant relationship in other
parameters studied.
The demographic characteristics and studied
parameters of patients are compared in Table 2.
Homocysteine levels were higher than normal in
14 (33%) patients in the control group. In the MTHFR
heterozygous group, 202 (73.5%) patients had high
homocysteine levels; in the homozygous group, 39 (79.1%)
patients. There was a significant difference between RP

existence in MTHFR mutation groups (P < 0.05, X2 =
40.60). The relationships between homocysteine levels and
MTHFR mutations are shown in Table 3.
The relationships between RP existence and MTHFR
mutations are shown in Table 4. RP existence was more
frequent in the MTHFR homozygous mutation group (P
< 0.05).
When the relationships between homocysteine
levels and RP existence are analyzed, 19 (6.9%) patients
experienced RP although they had normal blood
homocysteine levels. RP was not observed in 257 (93.1%)
patients with normal blood homocysteine levels. In
patients with high levels of homocysteine, 37 (33.0%)
experienced RP, while 56 (67.0%) did not. Homocysteine
levels and frequency of RP are shown in Table 5. The
relationships between RP and homocysteine levels were
analyzed using a chi-squared test. Similar to the results of
the MTHFR mutation positive group, RP was observed
more frequently in patients with elevated homocysteine
levels (P < 0.05, X2 = 14.51).
4. Discussion
A significant relationship between plasma homocysteine
levels and MTHFR gene mutations has been identified in
this study. Furthermore, RP was more frequently observed
in patients with hyperhomocysteinemia. Dietary folate
intake and MTHFR gene polymorphisms are major

Table 2. The demographic characteristics and laboratory findings of the control, heterozygous, and homozygous
groups.
Characteristics

Control

Heterozygous

Homozygous

P value

Age (years)

36.04 ± 0.8

39.5 ± 12.5

44.1 ± 13.1

0.08

Homocysteine (mg/mL)

8.06 ± 2.4

9.16 ± 3.9

14.76 ± 3.0

0.00

Vitamin B12 (pg/mL)

399.25 ± 198.6

406.05 ± 171.11

340.18 ± 196.27

0.24

Folic acid (ng/mL)

11.98 ± 6.09

9.11 ± 4.72

9.27 ± 3.77

0.19

Platelet (10 /uL)

256.93 ± 84.34

249.29 ± 76.02

253.46 ± 61.98

0.83

WBC* (103/mL)

7600 ± 2300

7787 ± 2270

7669 ± 2167

0.88

CRP**(mg/L)

8.4 ± 3.7

8.6 ± 3.6

7.6 ± 2.9

0.77

3

*White blood cell; **C reactive protein.
Table 3. Homocysteine levels and MTHFR gene mutations of patients.
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Normal

High

Total

Control

47 (77%)

14 (33%)

61 (100%)

MTHFR heterozygous

73 (26.5%)

202 (73.5%)

275 (100%)

MTHFR homozygous

13 (20.9%)

39 (79.1%)

52 (100%)

Total

133 (34.3%)

255(65.7%)

388 (100%)

P and X2
P < 0.05
X2 = 58.81
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Table 4. The existence of RP and MTHFR mutation.
Positive

Negative

Total

Control

9 (14.7%)

52 (85.3%)

61 (100%)

MTHFR heterozygous

22 (8%)

253 (92%)

275 (100%)

MTHFR homozygous

14 (26.9%)

38 (73.1%)

52 (100%)

Total

45 (11.6%)

343 (88.4%)

388 (100%)

P and X2
P < 0.05
X2 = 15.97

Table 5. Homocysteine levels and frequency of RP.

Homocysteine levels

RP
Positive

Negative

Total

Normal

19 (6.9%)

257 (93.1%)

276 (100%)

High

37 (33.0%)

75 (67.0%)

112 (100%)

Total

56 (14.4%)

332 (85.6%)

388 (100%)

contributing factors for plasma homocysteine levels [23].
The plasma level of homocysteine affects endothelial
functions. Folic acid treatment may have beneficial effects
on endothelial dysfunction by decreasing homocysteine
plasma levels [24,25]. However, Pullin et al. demonstrated
in their study that low-dose folate intake reduced
homocysteine levels, but endothelial functions did not
improve [26].
There are few studies associated with PRP and plasma
homocysteine levels. Marasini et al. [22] conducted a
study with 30 patients with systemic sclerosis, 12 patients
with PRP, and 20 healthy patients as the control group.
They inspected MTHFR mutations, homocysteine, von
Willebrand factor (vWF), folate, and vitamin B12 levels.
Plasma homocysteine levels were found to be higher in
patients with secondary RP than patients with primary RP
and healthy controls. Plasma folate and vitamin B12 levels
were lower and vWF levels were higher in the SRP group
compared to PRP or control groups. Levy et al. worked
with patients who had primary RP and systemic sclerosis
with RP; homocysteine levels were found significantly
higher in patients with primary RP and systemic sclerosis
patients rather than the control group, but there was no
significant difference between primary and secondary
groups with RP. Plasma folate levels of patients with
primary RP were lower than in the secondary RP and
control groups in the same study [27]. Similar results were
obtained in the study by Al-Awami et al. [28]. Forty-two
patients with connective tissue disorders such as SLE,
mixed connective tissue disease, or systemic sclerosis and
26 patients with PRP were enrolled; homocysteine levels
were analyzed in patients and compared with a control

P and X2

P < 0.05
X2 = 44.11

group of 45 healthy volunteers. No difference was found
between homocysteine levels of patients with primary and
secondary RP, but the average homocysteine levels in both
groups were found to be higher than those of the control
group. There were no differences in folate or vitamin B12
levels among the groups. Caramaschi et al. reported 60
patients with systemic sclerosis and secondary RP; the
mean homocysteine levels were found to be significantly
higher than in the control group; homocysteine levels were
significantly positively correlated to vascular degeneration
in the nail bed [29]. Czupryniak et al. reported 21 patients
with end-stage renal disease (ESRD) who were on a
hemodialysis program, 10 of whom had RP but 11 did
not, and compared them to 9 healthy controls. Serum
homocysteine levels were found to be significantly higher
in patients with RP compared to patients without RP [30].
Cheng et al. reported a study with 34 patients having
systemic lupus erythematosus and 20 healthy controls
[31]. Eleven of the patients had RP. Homocysteine levels
were found to be higher in SLE patients with RP than in
control patients without RP and healthy controls. All
these data are consistent with the results of this study.
Regardless of the existence of MTHFR mutation,
frequency of RP was found to be 11.5% in the entire study
population. This is a higher prevalence of RP compared
to the general population. This may be caused by female
patient dominance in the study, and possibly also because
the majority of female patients had MTHFR mutations.
Patients having homozygous MTHFR mutations have
higher levels of homocysteine, and homocysteinemia
in these patients more frequently causes endothelial
dysfunction and eventually higher rates of RP occurrence.
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In conclusion, RP was more frequently
observed in groups with MTHFR mutations and
hyperhomocysteinemia. Serum homocysteine levels
in patients with RP may be helpful for diagnosis. Gene
mutation screening will be useful in these patients. If
mutations are found, these patients must be assessed for
early treatment of hyperhomocysteinemia, and early
intervention with antithrombotic or antiaggregants must
be considered.
There were some limitations of the present study. There
was female dominance in the study population, as some
male patients who were eligible did not want to participate
in the study. Most of the participants included in the
study were female patients admitted to the gynecology

and obstetrics clinic. Due to recurrent miscarriage, the
numbers of patients evaluated for the MTHFR gene
mutation in gynecology and obstetrics clinics are more
frequent. Because of this, heterozygous and control groups
have more females than male patients. However, when
only the males are considered for MTHFR gene mutations,
17.16% were negative, 72.93% were heterozygous, and
9.9% were homozygous. These rates were 5.88%, 56.47%,
and 37.64% respectively in the females.
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